Pharmacopeia
Nifedipine
Core pharmacology
- Main Action
-Inhibition of L-type calcium channels leads to decreases myometrial SM → decreased SM contraction
- Presentation
available in sustained and immediate release oral formulations, 10-60mg
- Mechanism of action
Selectively dilates arterial resistance vessels. The ↓in arterial BP elicits sympathetic reflexes, with resulting tachycardia and positive inotropy.
- Physiological effects
Thus, arteriolar resistance and blood pressure are lowered, contractility and segmental ventricular function are improved, and heart rate and cardiac output are modestly increased.
- Distribution
lipid solubility moderately low, minimal BBB
- Protein binding
~90%
- Volume of distribution
0.62-1.12 L/kg
- Metabolism
Hepatic via CYP3A4 to inactive metabolites
- Excretion
Urine (60% to 80% as inactive metabolites); faeces
- Half-life
2-5 hours (↑ in liver failure)
- Route And Dose
PO 10-20mg BD.
- Class Group
Dihydropyridine calcium-channel blocker and arterial vasodilator.
- Indications Uses
Used for angina, hypertension including pregnancy-associated hypertension, Raynaud phenomenon and coronary arterial spasm.
- Absorption
Completely absorbed after oral administration, with oral bioavailability approximately 45-68% because of first-pass metabolism.
- Introduction
prototypical dihydropyridine calcium channel blocker
- Adverse Effects Toxicity
Common adverse effects are headache, flushing and dizziness from vasodilatation. Peripheral oedema, eye pain and gingival hyperplasia are also reported. Abrupt withdrawal after chronic therapy may cause rebound hypertension.